Autoantibodies and Cardiovascular Dysfunction: Cause or Consequence?

Nagatomo, Yuji; Tang, W.H. Wilson

doi:10.1007/s11897-014-0217-5

Cited by 17 publications

(11 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the role of the humoral response remains unclear. In this respect, the relevance of autoantibodies for CVD has been previously appreciated [42,43], but there is scarce data regarding AAA [44]. Our findings add a new layer of evidence to this setting and expand the current knowledge on autoantibodies, namely anti-HDL antibodies, in AAA.…”

Section: Discussionsupporting

confidence: 59%

IgG Anti-High Density Lipoprotein Antibodies Are Elevated in Abdominal Aortic Aneurysm and Associated with Lipid Profile and Clinical Features

Rodríguez‐Carrio

Lindholt

Canyelles

et al. 2019

JCM

View full text Add to dashboard Cite

High-density lipoproteins cholesterol (HDLc) levels are decreased in abdominal aortic aneurysm (AAA), which is hallmarked by autoimmunity and lipid aortic deposits. To investigate whether IgG anti-HDL antibodies were present in AAA and their potential association with clinical features, IgG anti-HDL and total IgG along with HDLc plasma levels were measured in 488 AAA patients and 184 controls from the Viborg Vascular (VIVA) study, and in tissue-conditioned media from AAA intraluminal thrombus and media layer samples compared to control aortas. Higher IgG anti-HDL levels were found in AAA compared to controls, even after correcting for total IgG, and after adjusting for potential confounders. IgG anti-HDL levels were correlated with aortic diameter in univariate and adjusted multivariate analyses. IgG anti-HDL antibodies were negatively associated with HDLc levels before and after correcting for potential confounders. Increased anti-HDL antibodies were identified in tissue-conditioned media from AAA samples compared to healthy aortas, with higher levels being observed in the media layer. In conclusion, increased IgG anti-HDL levels (both in plasma and in tissue) are linked to AAA, associated with aortic diameter and HDLc levels. These data suggest a potential immune response against HDL in AAA and support an emerging role of anti-HDL antibodies in AAA.

show abstract

Section: Discussionsupporting

confidence: 59%

IgG Anti-High Density Lipoprotein Antibodies Are Elevated in Abdominal Aortic Aneurysm and Associated with Lipid Profile and Clinical Features

Rodríguez‐Carrio

Lindholt

Canyelles

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…Cardiac-specific autoantibodies secreted by B cells also contribute to progressive cardiac myocyte damage, and their pathogenic role has been suggested in in vitro and in vivo disease models as well as clinical studies [42,43]. Unfortunately, we did not determine whether DCM-derived MDSCs could directly suppress B cell proliferation and IgG production because we don't have sufficient numbers and time to carry out such assays.…”

Section: Discussionmentioning

confidence: 99%

Activated Circulating Myeloid-Derived Suppressor Cells in Patients with Dilated Cardiomyopathy

Zhang

Wang

Wei

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Myeloid-derived suppressor cells (MDSCs) are increased in inflammatory and autoimmune disorders. This study aims to evaluate the significance of MDSCs in dilated cardiomyopathy (DCM) patients. Methods: In total, 42 newly hospitalized DCM patients and 39 healthy controls were enrolled in the study. The frequencies of circulating CD14⁺HLA-DR^-/low MDSCs were determined by flow cytometry. Then, the functional properties of MDSCs in suppressing T cell proliferation and interferon-gamma (IFN-γ) production were measured in a co-culture model. Then, mRNA expression levels of various important molecules in peripheral blood mononuclear cells were measured by real time polymerase chain reaction. Furthermore, correlation analyses between MDSC frequencies and cardiac function parameters were also performed. Results: The frequencies of circulating CD14⁺HLA-DR^-/low MDSCs were significantly elevated in DCM patients compared with healthy controls. It showed that MDSCs from DCM patients more effectively suppressed T cell proliferation and IFN-γ production compared with those from healthy controls, which was partially mediated by arginase-1 (Arg-1). In addition, the correlation analysis suggested that MDSC frequencies were negatively correlated with left ventricular ejection fraction (LVEF), while positively with N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with DCM. Conclusions: Circulating activated MDSCs might play significant immunomodulatory roles in the pathogenesis of DCM.

show abstract

“…Historical evidence for an immune role in DCM is demonstrated by the presence of autoantibodies against cardiac antigens including myosin, troponin and autonomic cardiac receptors. Molecular mimicry of infectious agents (e.g., Trypanosoma cruzi ) has been implicated in their formation, but they have also been shown to develop in animals immunised with the respective antigens who go on to develop myocarditis or a DCM‐like phenotype [108]. Whilst frequently present in DCM, their pathological role is uncertain.…”

Section: Diagnostic Strategiesmentioning

confidence: 99%

Dilated cardiomyopathy and chronic cardiac inflammation: Pathogenesis, diagnosis and therapy

et al. 2022

View full text Add to dashboard Cite

Dilated cardiomyopathy (DCM) is typically defined by left ventricular dilation and systolic dysfunction in the absence of a clear precipitant. Idiopathic disease is common; up to 50% of patients with DCM have no cause found despite imaging, genetic and biopsy assessments. Treatment remains focused on managing symptoms, reducing the risk of sudden cardiac death and ameliorating the structural and electrical complications of disease progression. In the absence of aetiologyspecific treatments, the condition remains associated with a poor prognosis; mortality is approximately 40% at 10 years. The role of immunemediated inflammatory injury in the development and progression of DCM was first proposed over 30 years ago. Despite the subsequent failures of three large clinical trials of immunosuppressive treatment (ATTACH, RENEWAL and the Myocarditis Treatment Trial), evidence for an abnormal adaptive immune response in DCM remains significant. In this review, we summarise and discuss available evidence supporting immune dysfunction in DCM, with a specific focus on cellular immunity. We also highlight current clinical and experimental treatments. We propose that the success of future immunosuppressive treatment trials in DCM will be dependent on the deep immunophenotyping of patients, to identify those with active inflammation and/or an abnormal immune response who are most likely to respond to therapy.

show abstract

Autoantibodies and Cardiovascular Dysfunction: Cause or Consequence?

Cited by 17 publications

References 85 publications

IgG Anti-High Density Lipoprotein Antibodies Are Elevated in Abdominal Aortic Aneurysm and Associated with Lipid Profile and Clinical Features

IgG Anti-High Density Lipoprotein Antibodies Are Elevated in Abdominal Aortic Aneurysm and Associated with Lipid Profile and Clinical Features

Activated Circulating Myeloid-Derived Suppressor Cells in Patients with Dilated Cardiomyopathy

Dilated cardiomyopathy and chronic cardiac inflammation: Pathogenesis, diagnosis and therapy

Contact Info

Product

Resources

About